Anzeige
❌
Mehr »
Samstag, 03.10.2026 - Börsentäglich über 12.000 News
Die Lizenz, über die niemand spricht, und warum Wettbewerber keine bekommen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AC4K | ISIN: US28106W1036 | Ticker-Symbol: 8EM
Tradegate
02.10.26 | 09:31
2,210 Euro
-5,15 % -0,120
1-Jahres-Chart
EDITAS MEDICINE INC Chart 1 Jahr
5-Tage-Chart
EDITAS MEDICINE INC 5-Tage-Chart
RealtimeGeldBriefZeit
2,2802,30009:49
2,2702,38002.10.

Aktuelle News zur EDITAS MEDICINE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
EDITAS MEDICINE Aktie jetzt für 0€ handeln
23.09.Editas raised to Buy at Guggenheim on cholesterol therapy1
23.09.TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday1
23.09.This Editas Medicine Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday5
23.09.Guggenheim-Hochstufung beflügelt Editas Medicine Aktie2
23.09.Guggenheim upgrades Editas Medicine stock rating on gene editing therapy1
09.09.Editas Medicine, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
09.09.Editas Medicine gewährt neuem Chief Medical Officer Aktienoptionen2
09.09.Editas Medicine grants stock options to new chief medical officer1
09.09.Editas Medicine, Inc.: Editas Medicine Reports Inducement Grants to New Chief Medical Officer3
08.09.Editas Medicine Names Dan Ory Chief Medical Officer1
08.09.Editas Medicine beruft Dan Ory zum neuen Chief Medical Officer2
08.09.Editas Medicine names Dan Ory as chief medical officer1
08.09.Editas Medicine, Inc.: Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer405Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development Appointment strengthens executive leadership team as...
► Artikel lesen
05.08.Editas Medicine, Inc.: Editas Medicine Announces Second Quarter 2026 Results and Business Updates566EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins,...
► Artikel lesen
04.08.Editas Medicine appoints Patrick Ellinor to board of directors1
04.08.Editas Medicine beruft Herz-Kreislauf-Spezialist Patrick Ellinor in den Verwaltungsrat1
04.08.Editas Medicine, Inc.: Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D.195CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today...
► Artikel lesen
18.06.Editas Medicine, Inc. - 8-K, Current Report3
26.05.Editas Medicine prices $125M stock offering with warrants23
26.05.Editas Medicine, Inc.: Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering12
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1